A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer

被引：54

作者：

Camidge, D. Ross

Gadgeel, Shirish M.

Weems, Garry Alan

Wilkins, H. Jeffrey

Johnson, Melissa Lynne

机构：

[1] Univ Colorado Denver, Aurora, CO USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Lycera Corp, Plymouth Meeting, PA USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS9111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

TPS9111

引用

页数：1